(Q33392366)

English

A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

arsenic trioxide

0 references

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Jaroslaw P. Maciejewski

2

object named as

Jaroslaw P Maciejewski

1 reference

Europe PubMed Central

26 July 2017

author name string

Mikkael A Sekeres

1

1 reference

Europe PubMed Central

26 July 2017

Harry P Erba

3

1 reference

Europe PubMed Central

26 July 2017

Manuel Afable

4

1 reference

Europe PubMed Central

26 July 2017

Ricki Englehaupt

5

1 reference

Europe PubMed Central

26 July 2017

Ronald Sobecks

6

1 reference

Europe PubMed Central

26 July 2017

Anjali Advani

7

1 reference

Europe PubMed Central

26 July 2017

Sherry Seel

8

1 reference

Europe PubMed Central

26 July 2017

Josephine Chan

9

1 reference

Europe PubMed Central

26 July 2017

Matt E Kalaycio

10

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

19 October 2010

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

117

1 reference

Europe PubMed Central

26 July 2017

6

1 reference

Europe PubMed Central

26 July 2017

1253-1261

1 reference

Europe PubMed Central

26 July 2017

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

21 January 2018

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

21 January 2018

Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

21 January 2018

The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

21 January 2018

Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

21 January 2018

Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

21 January 2018

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

21 January 2018

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

21 January 2018

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

21 January 2018

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

21 January 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

21 January 2018

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

21 January 2018

Myelodysplastic syndromes: incidence and survival in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

7 January 2021

based on heuristic

inferred from DOI database lookup

Myelodysplastic syndromes: a study of 101 cases according to the FAB classification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

7 January 2021

based on heuristic

inferred from DOI database lookup

Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

7 January 2021

based on heuristic

inferred from DOI database lookup

Myelodysplastic syndromes: analysis of 131 cases according to the FAB classification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

7 January 2021

based on heuristic

inferred from DOI database lookup

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

7 January 2021

based on heuristic

inferred from DOI database lookup

Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25686

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25686

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33392366&oldid=1858090279"